Alaunos Therapeutics appoints Michael A. Jerman as director, effective July 15, 2025

Alaunos Therapeutics, Inc.

Jerman fills vacancy from Dale Curtis Hogue's resignation; also joins Audit and Compensation Committees.
Jerman replaces Holger Weis on committees after Weis became CEO; Jerman will chair Audit Committee.
Compensation: $40k annual cash retainer, plus committee fees; initial option for 10,000 shares vesting over 36 months.
Prorated annual grant of 3,200 shares awarded; vesting subject to continued service through 2026 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.